306 related articles for article (PubMed ID: 37270060)
21. Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease.
Mills PJ; Caussy C; Loomba R
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):741-743. PubMed ID: 30954713
[TBL] [Abstract][Full Text] [Related]
22. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease.
Park MS; Han KH; Kim SU
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):501-11. PubMed ID: 24939348
[TBL] [Abstract][Full Text] [Related]
23. Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression.
Wu H; Liao B; Li X; Liu H; Gong M; Shi H; Xie S; Guo F; Chen K; Yan R; Zhao H; Li L; Zheng A; Liu Y; Wang Z
Infect Genet Evol; 2021 Sep; 93():104938. PubMed ID: 34029727
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer.
Philips GM; Chan IS; Swiderska M; Schroder VT; Guy C; Karaca GF; Moylan C; Venkatraman T; Feuerlein S; Syn WK; Jung Y; Witek RP; Choi S; Michelotti GA; Rangwala F; Merkle E; Lascola C; Diehl AM
PLoS One; 2011; 6(9):e23943. PubMed ID: 21912653
[TBL] [Abstract][Full Text] [Related]
25. Iron and liver fibrosis: Mechanistic and clinical aspects.
Mehta KJ; Farnaud SJ; Sharp PA
World J Gastroenterol; 2019 Feb; 25(5):521-538. PubMed ID: 30774269
[TBL] [Abstract][Full Text] [Related]
26. Liver diseases: what is known so far about the therapy with human amniotic membrane?
Guerra S; Mamede AC; Carvalho MJ; Laranjo M; Tralhão JG; Abrantes AM; Maia CJ; Botelho MF
Cell Tissue Bank; 2016 Dec; 17(4):653-663. PubMed ID: 27550013
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma and chronic persistent hepatitis.
Shikata T; Yamazaki S; Uzawa T
Acta Pathol Jpn; 1977 May; 27(3):297-304. PubMed ID: 200057
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Loomba R; Friedman SL; Shulman GI
Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
[TBL] [Abstract][Full Text] [Related]
29. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
Teng PC; Huang DQ; Lin TY; Noureddin M; Yang JD
Gut Liver; 2023 Jan; 17(1):24-33. PubMed ID: 36530125
[TBL] [Abstract][Full Text] [Related]
30. Blood reelin in the progression of chronic liver disease.
Sturm L; Roth L; Zoldan K; Schultheiss M; Boettler T; Huber JP; Kaeser R; Thimme R; Bettinger D
Adv Med Sci; 2021 Mar; 66(1):148-154. PubMed ID: 33561810
[TBL] [Abstract][Full Text] [Related]
31. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.
Kanda T; Goto T; Hirotsu Y; Moriyama M; Omata M
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30889843
[TBL] [Abstract][Full Text] [Related]
32. Hepatic stellate cells in inflammation-fibrosis-carcinoma axis.
Wang BB; Cheng JY; Gao HH; Zhang Y; Chen ZN; Bian H
Anat Rec (Hoboken); 2010 Sep; 293(9):1492-6. PubMed ID: 20652939
[TBL] [Abstract][Full Text] [Related]
33. Advancements in the Alcohol-Associated Liver Disease Model.
Zhu L; Li HD; Xu JJ; Li JJ; Cheng M; Meng XM; Huang C; Li J
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008929
[TBL] [Abstract][Full Text] [Related]
34. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
Wiering L; Subramanian P; Hammerich L
Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
[TBL] [Abstract][Full Text] [Related]
35. [Inflammation and Hepatic Fibrosis, Then Hepatocellular Carcinoma].
Kwon OS; Choi SH; Kim JH
Korean J Gastroenterol; 2015 Dec; 66(6):320-4. PubMed ID: 26691189
[TBL] [Abstract][Full Text] [Related]
36. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis.
Qi X; Schepers E; Avella D; Kimchi ET; Kaifi JT; Staveley-O'Carroll KF; Li G
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566616
[TBL] [Abstract][Full Text] [Related]
37. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
She S; Wu X; Zheng D; Pei X; Ma J; Sun Y; Zhou J; Nong L; Guo C; Lv P; Song Q; Zheng C; Liang W; Huang S; Li Q; Liu Z; Song Z; Li Y; Zhang Y; Kong W; You H; Xi J; Wang Y
J Hepatol; 2020 Mar; 72(3):506-518. PubMed ID: 31813573
[TBL] [Abstract][Full Text] [Related]
38. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway.
Zhao X; Fu J; Xu A; Yu L; Zhu J; Dai R; Su B; Luo T; Li N; Qin W; Wang B; Jiang J; Li S; Chen Y; Wang H
Cell Death Dis; 2015 May; 6(5):e1751. PubMed ID: 25950481
[TBL] [Abstract][Full Text] [Related]
39. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma.
Baglieri J; Brenner DA; Kisseleva T
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959975
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl
Chang CC; Yang Y; Gao DY; Cheng HT; Hoang B; Chao PH; Chen LH; Bteich J; Chiang T; Liu JY; Li SD; Chen Y
J Drug Target; 2018; 26(5-6):516-524. PubMed ID: 29251522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
